Terms: = Lung cancer AND KIF5B, ENSG00000170759, 3799, P33176, UKHC, KNS1, KNS, KINH
149 results:
1. Comparison of gene mutation profile in different lung adenocarcinoma subtypes by targeted next-generation sequencing.
Zhang S; Dong P; Pan Z; Chen Q; Zhu J; Mao Z
Med Oncol; 2023 Nov; 40(12):349. PubMed ID: 37935925
[TBL] [Abstract] [Full Text] [Related]
2. Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer.
Gao M; Zhang X; Yan H; Sun D; Yang X; Yuan F; Ju Y; Wang L; Wang J; Zhao W; Zhang D; Li L; Xu X; Ma J; Hu Y; Zhang X
Support Care Cancer; 2023 Nov; 31(12):671. PubMed ID: 37924363
[TBL] [Abstract] [Full Text] [Related]
3. Combined large cell neuroendocrine carcinoma, lung adenocarcinoma, and squamous cell carcinoma: a case report and review of the literature.
Zhu Z; Liu Y; Xu H; Ning H; Xia Y; Shen L
J Cardiothorac Surg; 2023 Aug; 18(1):254. PubMed ID: 37653509
[TBL] [Abstract] [Full Text] [Related]
4. MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition.
Riedel R; Fassunke J; Scheel AH; Scheffler M; Heydt C; Nogova L; Michels S; Fischer RN; Eisert A; Scharpenseel H; John F; Ruge L; Schaufler D; Siemanowski J; Ihle MA; Wagener-Ryczek S; Pappesch R; Rehker J; Bunck A; Kobe C; Keil F; Merkelbach-Bruse S; Büttner R; Wolf J
J Thorac Oncol; 2024 Jan; 19(1):160-165. PubMed ID: 37429463
[TBL] [Abstract] [Full Text] [Related]
5. Molecular characterization of MET fusions from a large real-world Chinese population: A multicenter study.
Xia H; Zhang J; Chen T; Wang M; Chen D; Si T; Liu Y
Cancer Med; 2023 Jul; 12(13):14015-14024. PubMed ID: 37326363
[TBL] [Abstract] [Full Text] [Related]
6. Intracranial Activity of Selpercatinib in Chinese Patients With Advanced
Cheng Y; Huang D; Zhou J; Zhou C; Sun Y; Wu L; Guo Y; Jingxin S; Zhang W; Lu S
JCO Precis Oncol; 2023 Jun; 7():e2200708. PubMed ID: 37315261
[TBL] [Abstract] [Full Text] [Related]
7. Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report.
Wu L; Cheng Y; Huang D; Sun Y; Zhou C; Zhou J; Guo Y; Shao J; Zhang W; Lu S
Anticancer Drugs; 2023 Oct; 34(9):1058-1064. PubMed ID: 37265026
[TBL] [Abstract] [Full Text] [Related]
8. Pathological characteristics and tumour immune microenvironment of lung malignancies with RET rearrangement.
Gao QY; Xiao FM; Lin XC; Chen YQ; Li YF; Lu C; Su JW; Tan QQ; Zhang CY; Yang J; Wu YL; Chen HJ; Yang JJ
Cancer Treat Res Commun; 2023; 35():100707. PubMed ID: 37121144
[TBL] [Abstract] [Full Text] [Related]
9. Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive lung cancers.
Rotow J; Patel JD; Hanley MP; Yu H; Awad M; Goldman JW; Nechushtan H; Scheffler M; Kuo CS; Rajappa S; Harada G; Clifford S; Santucci A; Silva L; Tupper R; Oxnard GR; Kherani J; Drilon A
Clin Cancer Res; 2023 Aug; 29(16):2979-2987. PubMed ID: 36996322
[TBL] [Abstract] [Full Text] [Related]
10. ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via
Chuang TP; Lai WY; Gabre JL; Lind DE; Umapathy G; Bokhari AA; Bergman B; Kristenson L; Thorén FB; Le A; Doebele RC; Van den Eynden J; Palmer RH; Hallberg B
Proc Natl Acad Sci U S A; 2023 Feb; 120(8):e2216479120. PubMed ID: 36791109
[TBL] [Abstract] [Full Text] [Related]
11. Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib.
Murciano-Goroff YR; Falcon CJ; Lin ST; Chacko C; Grimaldi G; Liu D; Wilhelm C; Iasonos A; Drilon A
J Thorac Oncol; 2023 May; 18(5):620-627. PubMed ID: 36657661
[TBL] [Abstract] [Full Text] [Related]
12. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With lung cancer Harboring a RET Fusion.
Aldea M; Marinello A; Duruisseaux M; Zrafi W; Conci N; Massa G; Metro G; Monnet I; Gomez Iranzo P; Tabbo F; Bria E; Guisier F; Vasseur D; Lindsay CR; Ponce-Aix S; Cousin S; Citarella F; Fallet V; Minatta JN; Eisert A; de Saint Basile H; Audigier-Valette C; Mezquita L; Calles A; Mountzios G; Tagliamento M; Remon Masip J; Raimbourg J; Terrisse S; Russo A; Cortinovis D; Rochigneux P; Pinato DJ; Cortellini A; Leonce C; Gazzah A; Ghigna MR; Ferrara R; Dall'Olio FG; Passiglia F; Ludovini V; Barlesi F; Felip E; Planchard D; Besse B
J Thorac Oncol; 2023 May; 18(5):576-586. PubMed ID: 36646211
[TBL] [Abstract] [Full Text] [Related]
13. Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors.
Riedel R; Fassunke J; Tumbrink HL; Scheel AH; Heydt C; Hieggelke L; Scheffler M; Heimsoeth A; Nogova L; Michels S; Weber JP; Fischer RN; Eisert A; Westphal T; Schaufler D; Siemanowski J; Ihle MA; Wagener-Ryczek S; Castiglione R; Pappesch R; Rehker J; Jürgens J; Stoelben E; Bunck A; Kobe C; Merkelbach-Bruse S; Sos ML; Büttner R; Wolf J
Eur J Cancer; 2023 Jan; 179():124-135. PubMed ID: 36521334
[TBL] [Abstract] [Full Text] [Related]
14. Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a kif5b-RET rearrangement: a case report.
Wu Y; Yan Z; Pan J; Chang X; Huang B; Luo D; Meng R; Shi H; Fan J; Nie X
World J Surg Oncol; 2022 Dec; 20(1):386. PubMed ID: 36471407
[TBL] [Abstract] [Full Text] [Related]
15. Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report.
Gu L; Ji W; Xu Y; Han Y; Jian H
Medicine (Baltimore); 2022 Nov; 101(47):e31480. PubMed ID: 36451418
[TBL] [Abstract] [Full Text] [Related]
16. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
[TBL] [Abstract] [Full Text] [Related]
17. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions.
Zhang Y; Chan S; He R; Liu Y; Song X; Tu ZC; Ren X; Zhou Y; Zhang Z; Wang Z; Zhou F; Ding K
Eur J Med Chem; 2022 Dec; 244():114862. PubMed ID: 36308779
[TBL] [Abstract] [Full Text] [Related]
18. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
Wang C; Zhang Z; Sun Y; Wang S; Wu M; Ou Q; Xu Y; Chen Z; Shao Y; Liu H; Hou P
J Transl Med; 2022 Sep; 20(1):390. PubMed ID: 36059009
[TBL] [Abstract] [Full Text] [Related]
19. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
Subbiah V; Cassier PA; Siena S; Garralda E; Paz-Ares L; Garrido P; Nadal E; Vuky J; Lopes G; Kalemkerian GP; Bowles DW; Seetharam M; Chang J; Zhang H; Green J; Zalutskaya A; Schuler M; Fan Y; Curigliano G
Nat Med; 2022 Aug; 28(8):1640-1645. PubMed ID: 35962206
[TBL] [Abstract] [Full Text] [Related]
20. Poor response to selpercatinib plus crizotinib in a rearranged during transfection fusion-positive patient with acquired selpercatinib-resistant MNNG HOS transforming amplification: a case report.
Meng Z; Zhang C; Zuo R; Zhu F; Wang Y; Mi R; Zhang M; Chen P
Anticancer Drugs; 2022 Aug; 33(7):682-685. PubMed ID: 35324532
[TBL] [Abstract] [Full Text] [Related]
[Next]
